| Carol K Fosso, MD | |
|
70 E 91st St Ste 204, Indianapolis, IN 46240-1564 | |
| (317) 872-4213 | |
| (317) 872-6388 |
| Full Name | Carol K Fosso |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 37 Years |
| Location | 70 E 91st St Ste 204, Indianapolis, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356332001 | NPI | - | NPPES |
| 100132220 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | 1037197 (Indiana) | Primary |
| Entity Name | Allergy And Asthma Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104926294 PECOS PAC ID: 2365636552 Enrollment ID: O20101102000153 |
News Archive
Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.
After a week of stepped-up health reform activity, today's headlines highlight that the White House is intensifying its final push by setting a deadline for congressional action. Meanwhile, though, the Democratic party continues to face rifts within its own caucus. Abortion coverage issues again posing challenges to securing Democratic votes.
When Francis Crick and James Watson discovered the double helical structure of deoxyribonucleic acid (DNA) in 1953, it began a genetic revolution to map, study, and sequence the building blocks of living organisms.
Uroplasty, Inc. announced today that its underwritten public offering of 4 million shares of its common stock was priced at $3.50 per share. Uroplasty has granted the underwriters of the offering an option to purchase up to an additional 600,000 shares of common stock within the next 30 days, solely to cover over-allotments, if any. All of the shares in the offering are being offered by Uroplasty. Uroplasty expects the offering to close on July 27, 2010, subject to customary closing conditions.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol K Fosso, MD 70 E 91st St Ste 204, Indianapolis, IN 46240-1564 Ph: (317) 872-4213 | Carol K Fosso, MD 70 E 91st St Ste 204, Indianapolis, IN 46240-1564 Ph: (317) 872-4213 |
News Archive
Boston Scientific Corporation today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing the performance of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in diabetic versus non-diabetic patients. Results demonstrated that despite the known increased risk of restenosis for diabetics versus non-diabetics in patients undergoing coronary revascularization, the TAXUS Element Stent had comparable levels of target lesion revascularization (TLR) and late loss in both diabetic and non-diabetic patients.
After a week of stepped-up health reform activity, today's headlines highlight that the White House is intensifying its final push by setting a deadline for congressional action. Meanwhile, though, the Democratic party continues to face rifts within its own caucus. Abortion coverage issues again posing challenges to securing Democratic votes.
When Francis Crick and James Watson discovered the double helical structure of deoxyribonucleic acid (DNA) in 1953, it began a genetic revolution to map, study, and sequence the building blocks of living organisms.
Uroplasty, Inc. announced today that its underwritten public offering of 4 million shares of its common stock was priced at $3.50 per share. Uroplasty has granted the underwriters of the offering an option to purchase up to an additional 600,000 shares of common stock within the next 30 days, solely to cover over-allotments, if any. All of the shares in the offering are being offered by Uroplasty. Uroplasty expects the offering to close on July 27, 2010, subject to customary closing conditions.
› Verified 4 days ago
Leanna-marie S Gershuni, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 9002 N Meridian St Ste 107, Indianapolis, IN 46260 Phone: 317-848-9441 Fax: 317-924-8239 | |
Simran K Jutla, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 705 Riley Hospital Dr, Indianapolis, IN 46202 Phone: 317-948-7208 Fax: 317-944-7245 | |
Dr. Douglas J. Horton, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 9002 N Meridian St Ste 107, Indianapolis, IN 46260 Phone: 317-848-9441 Fax: 317-924-8239 | |
Mark Holbreich, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 8902 N Meridian St, Ste. 100, Indianapolis, IN 46260 Phone: 317-574-0230 Fax: 317-574-0232 | |
Mason R Goodman, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1801 N Senate Blvd Ste 230, Indianapolis, IN 46202 Phone: 317-962-5820 Fax: 317-962-3916 | |
Liang Yeh Frank Wu, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 8402 Harcourt Rd, #606, Indianapolis, IN 46260 Phone: 317-872-4214 Fax: 317-872-6388 |